| |
|
|
|
Xtalks, online
2023 -5-18
Preclinical research and development (R&D) centers around workflows that generate more pathology data than any other phase of drug discovery and development. Leading pharmaceutical companies, biotechnology companies, and CROs are rapidly adopting digital pathology to drive efficiency and quality gains while capitalizing on the promise of their data.
In this webinar, Nathan Buchbinder, co-founder and Chief Product Officer of Proscia, a leader in digital and computational pathology, will share insights on how digital pathology is advancing preclinical R&D to streamline routine operations, improve the reproducibility of their results, and better leverage their pathology data. During this engaging session, you will explore:
How digital and computational pathology are addressing common pain points in preclinical R&D, such as lengthy timelines, and high study costs for GLP-compliant as well as non-regulated research and development
Real-world use case examples of how leading life sciences organizations are modernizing their routine workflows to drive quality and efficiency including toxpath scoring and peer review workflows
The impact of AI and computational applications in delivering ROI and capitalizing on digitized pathology data
The technology that’s enabling life sciences organizations to realize these benefits in practice, and strategies and key considerations to make the most of digital pathology adoption for preclinical studies and beyond.
Whether you’re a researcher, a pathologist, or simply interested in the latest technology trends in the life sciences, this webinar is not to be missed.
|
|
|
|
|
|
|
|
Organized by:
|
|
Xtalks |
|
|
Invited Speakers:
|
|
Nathan Buchbinder, Co-Founder & Chief Product Officer, Proscia
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
2023 -5-18
|
|
|
|
|
|
|
|
Registration:
|
|
Free registration
|
|
|
E-mail:
|
|
ajuurinen@xtalks.com
|
|
|
|
|
|
|
|
|